Corrigendum: Pazopanib in metastatic renal cancer: A "real-world" experience at national cancer institute "Fondazione G. Pascale" [Front. Pharmacol., 7, 287, (2016)] doi: 10.3389/fphar.2016.00287

In the original article, we have neglected to thank our funder, Novartis Farma S.p.A. The Funding Statement appears below. Funding Novartis Farma S.p.A. supported publication of this article. The authors apologize for this oversight. This error does not change the scientific conclusions of the article in any way. Conflict of Interest Statement The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.